Browse News

Found 756,624 articles

• 

  AC Immune Expands Vaccine Candidate to Down Syndrome

  1/26/2023

  Phase I/II data showed AC Immune’s anti-amyloid-beta vaccine candidate could safely elicit an antibody response in patients with Alzheimer’s disease. Now, it will expand to Down Syndrome patients.
• 

  Patient Death Pauses Another AML Trial

  1/26/2023

  Following the death of a patient, Magenta Therapeutics placed a hold on Phase I/II dose-escalation trial of its acute myeloid leukemia therapy.
• 

  Ocuphire to Advance Diabetic Retinopathy Drug Despite Missed Primary Endpoint

  1/26/2023

  Ocuphire Pharma's oral diabetic retinopathy drug missed the primary endpoint of an improvement in patient scores on the diabetic retinopathy severity scale.
• 

  Study Predicts Higher Prevalence of VEXAS Syndrome (Updated)

  1/26/2023

  A study published Tuesday in JAMA revealed VEXAS, a little-known syndrome with a high mortality rate, has a higher prevalence than previously thought.
• 

  10 Neuroscience Jobs in High Demand

  1/26/2023

  Whether you're a seasoned neuroscience professional or thinking about breaking into this field, check out our list of neuroscience jobs in high demand to help with your job search. 

• Panbela Announces Pricing of Approximately $15 Million Public Offering

  1/26/2023

  Panbela Therapeutics, Inc. today announced the pricing of a public offering of (i) 6,675,000 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 13,350,000 shares of its common stock.

• AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

  1/26/2023

  AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the first interim safety, tolerability and immunogenicity findings from the Phase 1b/2 ABATE trial of its anti-amyloid-beta (Abeta) vaccine ACI-24.060 in patients with prodromal Alzheimer’s disease (AD).

• Nogra Pharma announces out-licensing agreement with Torii Pharmaceutical for Japan for New Chemical Entity topical acne treatment

  1/26/2023

  Nogra Pharma today announces it has entered into an out-licensing agreement with Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551), to further develop and commercialise NAC-GED-0507 in Japan for the treatment of acne vulgaris.

• BioCentriq Releases Results of Study Designed to Test Transfection of T-cells Using Kytopen's Flowfect® Technology

  1/26/2023

  BioCentriq, Inc announced today that they've completed a study designed to test transfection of T-cells with GFP mRNA for evaluation of cell viability, transfection efficiency, and post transfection growth using Kytopen's Flowfect® technology.

• Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization

  1/26/2023

  Bone Biologics Corporation announces it has engaged Avania as the contract research organization (CRO) for the Company’s pilot clinical trial with NB1.

• Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & Europe

  1/26/2023

  Jaguar Health, Inc. today provided updates regarding the Company's focus on rare and orphan disease indications: short bowel syndrome (SBS), microvillus inclusion disease (MVID), and cholera.

• Elixirgen Therapeutics Enters Memorandum of Understanding with Hitachi Global Life Solutions for the Development of Micro GMP Suites for Cell Therapy Administration

  1/26/2023

  Elixirgen Therapeutics, Inc. today announced that it has entered a memorandum of understanding with Hitachi Global Life Solutions, Inc. (Hitachi GLS) for the development of Micro GMP suites to facilitate cell therapy administration.

• LAPIX Therapeutics Inc. Announces a Successful Conclusion of its Pre-IND Meeting Request with the U.S. FDA

  1/26/2023

  LAPIX Therapeutics, Inc. today announced the successful outcome of its pre-IND meeting request with the U.S. Food and Drug Administration (FDA).

• FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy

  1/26/2023

  Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved its Proclaim™ XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes.

• XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina

  1/26/2023

  XyloCor Therapeutics today announced completion of the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) designed to assess the safety and preliminary evidence of efficacy of lead gene therapy candidate XC001 (encoberminogene rezmadenovec) in patients with refractory angina.

• Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

  1/26/2023

  Soleno Therapeutics, Inc. today announced that results from the Company’s previously completed Phase 3 DESTINY PWS (C601) trial of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi Syndrome (PWS) have been published in a peer-reviewed journal.

• Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)

  1/26/2023

  Coya Therapeutics, Inc. announced the recent publication of an article entitled “Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s Disease” in the peer reviewed journal Acta Neuropathologica Communications.

• Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

  1/26/2023

  Centessa Pharmaceuticals plc today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2a first-in-human, clinical trial of LB101 for the treatment of solid tumors.

• Know Labs, Inc. Names Ron Erickson Chief Executive Officer; Former CEO Phil Bosua Becomes a Technology Consultant to the Company

  1/26/2023

  Know Labs, Inc. Names Ron Erickson Chief Executive Officer; Former CEO Phil Bosua Becomes a Technology Consultant to the Company.

• Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

  1/26/2023

  Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™).